FAKTOR-OPTIONSSCHEIN - ELI LILLY & CO | Delayed Deutsche Boerse AG 13:30:15 28/05/2024 BST | ||
| 0.21 EUR | 0.00% |
|
| Current month | -16.00% | ||
| 1 month | -30.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 28/05/24 | 0.21 | 0.00% |
| 27/05/24 | 0.21 | 0.00% |
| 24/05/24 | 0.21 | 0.00% |
| 23/05/24 | 0.21 | -4.55% |
| 22/05/24 | 0.22 | +4.76% |
Delayed Quote Deutsche Boerse AG
Last update May 28, 2024 at 01:30 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| WKN | SN2V8F |
| ISIN | DE000SN2V8F4 |
| Date issued | 03/06/2022 |
| Strike | 311.1 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.72 € |
|---|---|
| Lowest since issue | 0.2 € |
| Spread | 0.01 € |
| Spread % | 4.55% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
807.4
USD
Average target price
850.8
USD
Spread / Average Target
+5.37%
- Stock Market
- Certificates
- Certificat
